Table 1.

GLP‐1 RAs target six of the eight core defects evident in type 2 diabetes

8 core defects in type 2 diabetes 5	GLP‐1 RAs target 6 of the 8 core defects
Impaired insulin secretion Increased glucagon secretion Increased hepatic glucose Neurotransmitter dysfunction GI tract/decreased incretin effect Decreased glucose uptake Increased glucose reabsorption Increased lipolysis	Enhanced appropriate pancreatic β‐cell (insulin and amylin) secretion Pancreatic α‐cell (glucagon) suppression Decreased liver glucose production Increased satiety through central nervous system Slowed gastric emptying time Increased insulin uptake in peripheral tissue via weight loss

Abbreviations: GI, gastrointestinal; GLP‐1 RA, glucagon‐like peptide‐1 receptor agonist; α, alpha; β, beta.